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Abstract. The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000. To understand
why some national programs have been more successful than others, a panel of individuals with expertise in LF
elimination efforts met to assess available data from programs in 8 countries. The goal was to identify: 1) the factors
determining success for national LF elimination programs (defined as the rapid, sustained reduction in microfilaremia/
antigenemia after repeated mass drug administration [MDA]); 2) the priorities for operational research to enhance LF
elimination efforts.
Of more than 40 factors identified, the most prominent were 1) initial level of LF endemicity; 2) effectiveness of vector
mosquitoes; 3) MDA drug regimen; 4) population compliance.
Research important for facilitating program success was identified as either biologic (i.e., [1] quantifying differences
in vectorial capacity; [2] identifying seasonal variations affecting LF transmission) or programmatic (i.e., [1] identifying
quantitative thresholds, especially the population compliance levels necessary for success, and the antigenemia or
microfilaremia prevalence at which MDA programs can stop with minimal risk of resumption of transmission; [2]
defining optimal drug distribution strategies and timing; [3] identifying those individuals who are “persistently non-
compliant” during MDAs, the reasons for this non-compliance and approaches to overcoming it).
While addressing these challenges is important, many key determinants of program success are already clearly
understood; operationalizing these as soon as possible will greatly increase the potential for national program success.
BACKGROUND AND APPROACH
Since the official launch of the Global Program to Elimi-
nate Lymphatic Filariasis (GPELF) in 2000,1 almost 2 billion
doses of once-yearly anti-filarial drug treatment have been
administered to over 570 million people through national pro-
grams in 48 of the world’s 83 endemic countries.2 It is not
surprising that some of these programs have been more suc-
cessful than others. Now that a number of the early programs
are approaching the point at which they can contemplate
stopping the MDA component of their programs, it is pos-
sible to look retrospectively to identify factors that have in-
fluenced their outcomes. Such evaluation provides an oppor-
tunity to guide ongoing and still-to-be-initiated national pro-
grams toward adopting more successful strategies, and it
identifies key biologic, epidemiologic, and programmatic un-
certainties that might be addressed through targeted research.
Collection of detailed analytical data has not been a stan-
dard component of most national MDA programs, so the
richest source of information for identifying potential deter-
minants that affect program outcome lies with those programs
working closely with research teams from either government
research institutions or academia. In some instances these
collaborating research teams have directly tracked the
progress of the national programs, and in others they have
made detailed observations at study sites where treatment
activities were carried out in parallel to those of the national
program.
To capture the experiences of programs that have been
closely monitored (epidemiologically, entomologically, and
through laboratory studies) in different parts of the world,
investigators from programs in 8 countries (Table 1) provided
information identifying successes and failures within each
program and the likely reasons for these outcomes. Although
program “success” can have many dimensions, here the prin-
cipal measure of success was the decrease in microfilaremia
prevalence, a sine qua non of LF elimination. The specific
factors evaluated in relation to this marker of success—either
having a positive influence (i.e., leading toward greater im-
pact or shorter duration of MDA activities) or a negative
influence (i.e., leading toward lesser impact or longer dura-
tion of MDA activities)—are detailed in Table 2. Some of
these factors represent determinants that will have an effect
on program outcome regardless of how effectively the pro-
gram itself is carried out (Table 2a), whereas others relate
principally to the operational effectiveness of the programs
themselves (Table 2b). The conclusions in Table 2 largely
reflect the considered assessment and consensus of the inves-
tigators themselves after analysis and discussion of, in most
instances, published data describing the impact of MDA on
* Address correspondence to Dominique Kyelem or Eric A. Ottesen,
Lymphatic Filariasis Support Center, Task Force for Child Survival
and Development, Decatur, Georgia. E-mails: dkyelem@taskforce
.org and eottesen@taskforce.org
Am. J. Trop. Med. Hyg., 79(4), 2008, pp. 480–484
Copyright © 2008 by The American Society of Tropical Medicine and Hygiene
480
microfilaria prevalence and transmission3–19 and, in other cases,
less formal reports of LF elimination program activity.20–22
DETERMINANTS AFFECTING
PROGRAM OUTCOME
More than 40 different determinants affecting program out-
come were identified and described as leading to either
greater or lesser likelihood of success (defined as the rapid
and sustained fall in the prevalence of microfilaremia) for the
MDA-based LF elimination programs (Table 2).
Among the most prominent factors to affect program out-
come were: 1) the initial level of LF endemicity (i.e., preva-
lence and density of microfilaremia); 2) the competence and
vectorial capacity of the local vector; 3) the drug regimen used
for the MDAs; and 4) both population coverage* and popu-
lation compliance.†
Some of the determinants noted in Table 2 are not easily
changed—particularly those that are biologic/epidemiologic
in nature or those that reflect the underlying socioeconomic
and political environments of the endemic areas. Despite
their being relatively unchangeable, however, programs do
need to recognize their influence when implementation strat-
egies are being developed.
Other determinants are more readily modifiable—such as
compliance within the endemic communities and coverage of
the target population. These, in turn, are heavily dependent
on 1) the operational effectiveness of the programs (especially
social mobilization, supervision and monitoring), 2) the ad-
equacy of resources (both funding and human), and 3) the
political commitment to support the program.
IDENTIFYING RESEARCHABLE ISSUES
Although many of the factors identified in Table 2 are
not amenable to research or have been so well documented
* Defined by the proportion of the population targeted by the pro-
gram that was provided with the appropriate drugs.
† Defined by the proportion of eligible individuals actually ingesting
the drugs provided to them.
TABLE 1
National LF elimination activities assessed in this perspective
Program country LF parasite No. of MDAs
Burkina Faso Wuchereria bancrofti 5
Egypt W. bancrofti 5
Haiti W. bancrofti 5
India W. bancrofti 9
Indonesia Brugia timori 6
Kenya W. bancrofti 2
Nigeria W. bancrofti 6
Papua New Guinea W. bancrofti 7
TABLE 2a
Determinants influencing outcome of LF elimination programs
Factor Positive influence* Negative influence†
Readily
changeable
Important/
researchable
Biologic/epidemiologic/therapeutic
Endemicity (prevalence/density) Low High No 
Human population Small Large No
Endemic areas 1) Easily accessed 1) Remote No
2) Rural 2) Urban
Vector density Low high Yes 
Vector species Anopheles (? some better
than others)
Aedes or Culex No 
Transmission Seasonal Year-round No 
Parasite species Anthropophilic Brugia W. bancrofti No
MDA treatment regimen DEC (diethylcarbamazine) +
albendazole
Ivermectin + albendazole +/− 
Ivermectin dosage in regimen 400 mcg/kg 150–200 mcg/kg Yes 
Parasite responsiveness to treatment Excellent Residual mf/ag-emia No
Contiguous endemic areas Under MDA treatment Untreated Yes 
Sympatric Loa loa No Yes No
Sympatric zoophilic Brugia No Yes No 
Economic/political/social
Economic development of endemic
area
High (including housing,
roads)
Low, with poor physical
infrastructure
No
Administrative development of
endemic area
High overall performance Low performance record No
Health system infrastructure Good (including local health
units)
Poor, with weak national
MOH
No
Urban population: socio-economic
status
Lower (more difficult to reach,
easier to treat)
Higher (easier to reach,
more difficult to treat)
No 
Political stability, security Good Poor, high security risk No
Political commitment for NPELF Strong Minimal Yes
Compliance (people taking the drugs) High compliance rate; no
persistent non-compliance
Persistent non-compliance
or poor compliance rate
Yes 
Evident morbidity in population High (leads to perception of
importance)
Low (inhibits recognition
of importance)
No
Past experience of population with
LF or other MDA programs
Good results, minimal
inconvenience
Poor quality drugs, adverse
reactions
No
Migration from other endemic areas Minimal Extensive No 
* Leading to greater impact or shorter duration of MDA activities.
† Leading to lesser impact or longer duration of MDA activities.
MDA  mass drug administration; NPELF  National Program to Eliminate Lymphatic Filariasis; MOH  Ministry of Health.
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previously as to require little or no further study, the ef-
fects of almost one-third of the identified determinants
are poorly understood, and they require further study. Some
reflect current uncertainties in the biology of the parasite
and vector (including their interactions with each other and
the human host); others reflect uncertainties about how
best to design national programs to ensure success; and still
others indicate uncertainties in the way people respond to
MDAs.
“Biologic” research priorities. Two vector/parasite biologic
issues, if more well defined, could have particular impact on
program success: 1) quantifying the differences in vector com-
petence (microfilaria uptake, L3 production) among the dif-
ferent vector species, particularly the anophelines in Africa—
as this would better define the “force of infection” that indi-
vidual programs must confront and would affect decisions
about the frequency and duration of MDAs required to in-
terrupt LF transmission; 2) identifying potential seasonal
variations of relevance to LF transmission (microfilaremia in
humans, biting patterns in mosquitoes) in different endemic
regions—as this might open opportunities to tailor the timing
of MDAs to maximize their impact toward interrupting LF
transmission.
“Programmatic” research priorities. A better quantitative
understanding of the operational factors essential for pro-
gram success would be particularly valuable for improving
program outcome. Specifically, these factors would include:
1) the levels of population compliance required during MDAs
to achieve interruption of transmission (and the levels of non-
compliance or systematic non-compliance that still permit LF
elimination); 2) the levels of microfilaria (mf)-positivity or
antigen-positivity at which the MDA component of programs
can safely be stopped (i.e., an understanding of the “natural
history” and programmatic implications of persistent antigen-
emia in mf-negative individuals and of low-level microfilare-
mia prevalence in communities after multiple rounds of
MDA); 3) the number of rounds of MDA required for success
in different epidemiologic situations—perhaps fewer in low
endemicity areas and more, even with supplemental measures
including vector control and enhanced drug regimens, in
other epidemiologic settings.
Resolving programmatic uncertainties related to conduct of
the MDAs themselves could also greatly increase the likeli-
hood of individual program success. Particularly important
are 1) defining the optimal drug distribution methods and
strategies (Directly Observed Treatment [DOT] being the
TABLE 2b
Factors affecting operational effectiveness of LF elimination programs
Factor Positive influence Negative influence
Readily
changeable
Important/
researchable
Global program guidelines Detailed, comprehensive Imprecisely defined goals, tools,
strategies (compliance, # MDAs,
monitoring tools, sampling
strategies, stopping criteria)
Yes
Mapping of LF and other NTDs Complete Incomplete Yes
Program management, leadership Strong Weak Yes
Advocacy and fund-raising Active and effective Poor or non-existent Yes
“Personpower” Sufficient, well-trained, conscientious Shortage, unskilled or untrained Yes
Drug distributors Well trained, well informed, compensated Poorly motivated and trained Yes
Social mobilization Strong (IEC/COMBI), with involvement of
village leaders
Inadequate Yes 
Drug quality High and consistent Uncertain or poor Yes
Drug supply/delivery Timely and coordinated for 2-drug delivery Unreliable, uncoordinated Yes
MDA organization Well timed (dates, duration) Shifting dates, conflicting dates Yes
Drug administration By Directly Observed Treatment Not DOT Yes 
Treatment “coverage” (tablets
distributed)
High (estimated > 70% total population) Low Yes 
Treatment of “side reactions” Provision for rapid, effective management
(medical and “political”)
Inadequate response to person and
community needs
Yes
Morbidity management Strong program in place for lymphedema
management and hydrocoele surgery
Minimal attention to morbidity
issues
Yes
Monitoring Independent, routine; following process
indicators, using good sampling strategies
Insufficient frequency or attention
to detail
Yes
Evaluation Baseline mf- or ag-emia and reassessment
at defined intervals or potential program
end-point, using good sampling strategies
No baseline values; poor sampling
strategy
Yes 
Adjunctive tools to
eliminate LF
Vector control, twice-yearly MDA or
DEC-salt supplements in place
No adjunctive measures Yes 
LF’s relation to other NTD
Programs
Integration or strong coordination in place National program operates
independently
Yes 
Community understanding Recognizes multiple benefits of MDA
(on LF, on intestinal parasites etc.)
Inadequate information on
program’s full benefits to
the population
Yes 
Partnering organizations Multiple and coordinated Few or uncoordinated Yes
Funding for LF program Sufficient (best from national budget line) Inadequate, without ensured
continuity
Yes
Link between national program
and research community
Good collaboration; shared responsibility Competition, distrust Yes
MDAmass drug administration; LF lymphatic filariasis; NTD neglected tropical diseases; IEC/COMBI information education communication/communication for behavioral impact;
DOT  directly observed treatment; DEC  diethylcarbamazine.
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“gold standard”) for use in different settings—including
“problem settings” such as refugee, migrant, or urban areas;
2) determining the importance of interruptions in the planned
yearly implementation of MDAs; 3) identifying the impor-
tance of conducting the MDAs in relation to transmission
seasonality; and 4) understanding whether the effectiveness
of MDA-based programs in Brugia endemic areas is affected
by sympatric zoonotic Brugia infections.
“Community-focused” research priorities. The most im-
portant community-related uncertainty is the issue of compli-
ance. It will be valuable to develop “compliance profiles” of
communities to identify those groups of individuals who re-
main “persistently non-compliant” during MDAs (e.g., chil-
dren, upper socioeconomic classes, young men, older ages),
and then to determine the causes of this non-compliance and
effective approaches to overcoming it.
WAY FORWARD
It is unlikely that studies will be carried out, or answers
found, for all of these researchable questions in the near fu-
ture. There are financial constraints, limitations in available
study opportunities, and the fact that for some of these ques-
tions the essential research tools to address them are not yet
in hand. However, because each issue is important and be-
cause answers to any can certainly lead to improvements in
program design or execution, every opportunity to address
them should be taken.
Program improvement, moreover, need not await the out-
come of more research. The extensive programmatic experi-
ence summarized in Table 2 clearly identifies situations where
specific steps can be taken immediately to improve the like-
lihood of success for LF elimination programs. Key determi-
nants of successful outcomes have already been identified; the
challenge for the Global Program now is to support national
program managers in taking the right steps as quickly as pos-
sible.
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